Projects per year
Personal profile
University profile
Medicinal chemistry research in Dr. David Rotella's lab is a collaborative exercise where we engage other scientists with complimentary interests. Currently, they are engaged in discovery of protein kinase inhibitors for anti infective and anti inflammatory applications, in the discovery of new agents useful for the potential treatment of neurodegenerative diseases and enzyme inhibitors that can be used to treat botulism poisoning. Dr. Rotella is working with others at MSU as well as scientists in other universities and research institutes.
Research interests
Focused on drug discovery for CNS and neglected diseases.
Scholarly Interests
Medicinal chemistry. Drug discovery, hit to lead and lead optimization, medicinal chemistry, CNS, cardiovascular and metabolic disease expertise, intellectual property and expert witness.
Faculty/Media Expert
Expert on Medicinal chemistry, pharmaceuticals, and drug discovery.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Pharmacologic Inhibition of PDE11A for Age-Related Memory Disorders
Rotella, D., Hoffman, C. S. & Kelly, M.
15/09/20 → 30/04/24
Project: Research
-
Development of inhibitors of P. falciparum cGMP dependent protein kinase (PfPKG) for malaria chemoprevention
Bhanot, P., Rotella, D. & Siekierka, J.
National Institute of Allergy and Infectious Diseases
1/08/17 → 31/07/21
Project: Research
-
Successes in antiviral drug discovery: a tribute to Nick Meanwell
Rotella, D. P., 2023, (Accepted/In press) In: Medicinal Chemistry Research.Research output: Contribution to journal › Review article › peer-review
Open Access -
A novel series of putative Brugia malayi histone demethylase inhibitors as potential anti-filarial drugs
Kreiss, T., Eck, T., Hart, B., Tummalapalli, S., Rotella, D. & Siekierka, J., 2022, In: PLoS Neglected Tropical Diseases. 16, 3, e0010216.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Characterization of Competitive Inhibitors of Plasmodium falciparum cGMP-Dependent Protein Kinase**
Eck, T., Laureano de Souza, M., Delvillar, M., Ashraf, K., Yadav Bheemanaboina, R. R., Chakrasali, R., Kreiss, T., Siekierka, J. J., Rotella, D. P., Bhanot, P. & Goodey, N. M., 2022, (Accepted/In press) In: ChemBioChem.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Discovery of Imidazole-Based Inhibitors of Plasmodium falciparum cGMP-Dependent Protein Kinase
Bheemanaboina, R. R. Y., De Souza, M. L., Gonzalez, M. L., Mahmood, S. U., Eck, T., Kreiss, T., Aylor, S. O., Roth, A., Lee, P., Pybus, B. S., Colussi, D. J., Childers, W. E., Gordon, J., Siekierka, J. J., Bhanot, P. & Rotella, D. P., 2021, (Accepted/In press) In: ACS Medicinal Chemistry Letters.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Plasmodium falciparum cGMP-Dependent Protein Kinase – A Novel Chemotherapeutic Target
Rotella, D., Siekierka, J. & Bhanot, P., 3 Feb 2021, In: Frontiers in Microbiology. 11, 610408.Research output: Contribution to journal › Review article › peer-review
Open Access5 Scopus citations